SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for
cancer cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in
treating children with recurrent or progressive brain tumors.